Glancy Prongay & Murray LLP (GPM) announces an investigation on behalf of AVEO Pharmaceuticals, Inc. (AVEO or the Company) (NASDAQ: AVEO) investors concerning the Company and its officers possible violations of federal securities laws.
If you are a shareholder who suffered a loss, click here to participate.
If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected], or visit our website at www.glancylaw.com.
On January 31, 2019, AVEO announced it would not file a New Drug Application for tivozanib (FOTIVDA). According to AVEO, the FDA indicated that these preliminary OS results do not allay their concerns about the potential detriment in OS outlined in the complete response letter dated June 6, 2013. AVEO plans to make a NDA filing decision following the availability of more mature OS results. On this news, shares of AVEO fell $1.07 per share, or over 60%, to close at $0.70 per share on January 31, 2019, thereby injuring investors.
If you purchased AVEO securities, have information, or would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, of GPM, 1925 Century Park East, Suite 2100, Los Angeles, CA 90067 at 310-201-9150, Toll-Free at 888-773-9224, or visit our website at www.glancylaw.com. If you inquire by email please include your mailing address, telephone number, and the number of shares purchased.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.